StockNews.AI
RCEL
StockNews.AI
124 days

AVITA Medical to Announce First Quarter 2025 Financial Results

1. AVITA Medical to report Q1 2025 financial results on May 8, 2025. 2. Conference call scheduled to discuss financial highlights and results. 3. RECELL System approved by FDA for burn and defect treatments. 4. AVITA holds exclusive marketing rights for key products in the U.S. 5. RECELL system also accepted in international markets like Australia and Europe.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings report may show strong growth potential, reinforcing market confidence in RCEL.

How important is it?

Earnings results and growth prospects significantly affect stock pricing and investor sentiment.

Why Short Term?

Immediate investor interest likely as results approach, reflecting on near-term performance.

Related Companies

AVHMDGLMGEN
VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 9, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by telephone, please register in advance to receive dial-in details and a personal PIN using the following link: https://register-conf.media-server.com/register/BI88e9b0f5d021416f94e97d9729bf6cfa. A replay of the webcast will be available shortly after the live event on the Investor Relations website. About AVITA Medical, Inc.AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute both Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan. To learn more, visit www.avitamedical.com. Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Related News